Projet BICEPS (Horizon Europe, appel à projets 2023)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

Decades of research into Parkinson's disease (PD) have fallen short in fully comprehending its mechanisms, leaving us without a cure. Current treatments merely alleviate symptoms temporarily, but are unable to impede the progression of the disease. Clearly, PD research has hit a wall, and new approaches are needed. Recent discoveries of the involvement of the peripheral immune system in PD have sparked a groundbreaking proposition by BICEPS: PD must be considered a systemic disease with an immune response involving both brain and periphery. Thus, to revolutionize PD research, we must shift away from the neuro-centric approach of past decades and extend our focus to studying the immune system outside the brain. Furthermore, recent advancements, such as systems biology and artificial intelligence (AI)-driven data mining, diagnosis, and drug development, hold significant promise for advancing PD research.  Therefore, BICEPS is uniting PD researchers, immunologists, and experts in AI and systems biology from leading European academic institutions, startup companies, and established pharmaceutical firms into a unique consortium. The primary objective is to train a new generation of PD researchers with interdisciplinary expertise in these fields.  This ambitious goal will be realized through an intensive training program that encompasses cutting-edge methodologies, encourages innovation, nurtures transferable skills, and provides immersive, hands-on research experiences. Thereby, the BICEPS network aims to shape the future of PD research by adopting a fresh perspective and expediting the development of diagnostics and therapies for PD, with a particular focus on the immune system.

Mots clés : peripheral immune system, macrophages, t cells, parkinson s disease, disease mechanisms

Participants :
- Sulfateq b.v. (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 274370.4 €
- German Center for Neurodegenerative Diseases (Allemagne) — Partner, associated partner, Recherche, subvention : 0.0 €
- Association europeenne pour la maladie de parkinson (Belgique) — Partner, associated partner, Autres, subvention : 0.0 €
- Lundbeck (Denmark) (Danemark) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 301788.0 €
- Anacalypsis therapeutics idiotiki kefalaiouchiki etaireia (Grèce) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 240098.4 €
- Université libre de Berlin (Allemagne) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université d'Oxford (Royaume-Uni) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université de Belgrade (Serbie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 421689.6 €
- Université nationale et capodistrienne d'Athènes (Grèce) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 240098.4 €
- Université de Groningue (Pays-Bas) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 823111.2 €
- Metasysx gmbh (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 260539.2 €
- Bayer (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 260539.2 €
- Süleyman Demirel University (Turquie) — Partner, associated partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Université d'Aarhus (Danemark) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 603576.0 €
- Semikal teknoloji sanayi ve tic. ltd. sti. (Turquie) — Partner, associated partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Hôpital universitaire de la Charité de Berlin (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 463180.8 €